Skip to main content


Latest articles

30-10-2020 | Diabetes | News | Article

Diabetes does not impair COVID-19 antibody response

The humoral immune response to SARS-CoV-2 infection is similar in people with and without diabetes and is not influenced by hyperglycemia, research suggests.

29-10-2020 | Diabetes | News | Article

Improving glycemic control may reduce AKI risk in people with type 2 diabetes, CKD

Poor glycemic control is associated with acute kidney injury risk in people with type 2 diabetes and chronic kidney disease, according to results from an observational study.

28-10-2020 | Diabetes | News | Article

Canagliflozin linked to reduced anemia risk in people with type 2 diabetes, CKD

Treatment with the SGLT2 inhibitor canagliflozin is associated with a reduced risk for anemia-related outcomes among people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.

26-10-2020 | Diabetes | News | Article

Researchers propose early-onset type 2 diabetes phenotype

Younger age at onset of type 2 diabetes is associated with a significantly increased risk for cardiovascular death, as well as an increased likelihood of having offspring who will also develop diabetes, Framingham Heart Study data show.

23-10-2020 | Diabetes | News | Article

FIDELIO-DKD: Finerenone offers new treatment option for diabetic CKD

The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.

23-10-2020 | Diabetes | News | Article

Type 1 diabetes identified in earliest weeks of life

Researchers have identified infants as young as 3 months with probable type 1 diabetes, raising the possibility that the disease process could in some cases begin before birth.

21-10-2020 | Diabetes | News | Article

Obesity may be less impactful for older COVID-19 patients with type 2 diabetes

Obesity is a significant predictor of poor COVID-19 outcomes in patients who also have type 2 diabetes, but only in those up to the age of 75 years, report French researchers.

20-10-2020 | Diabetes | News | Article

Genetic data do not back vitamin D link to type 2 diabetes

Genetic analyses indicate that there is no causal association between vitamin D levels and type 2 diabetes, even though the association appears to be strong in observational data.

19-10-2020 | Diabetes | News | Article

CGM data followers can give life quality boost

Sharing continuous glucose monitoring data with a chief follower has multiple quality of life and health benefits for people with type 1 diabetes, a study shows.

16-10-2020 | Diabetes | News | Article

Metformin use might have neuroprotective effects in older patients with type 2 diabetes

Results from an observational study suggest that the use of metformin in older patients with type 2 diabetes is associated with a reduced decline in both global cognition and executive function, and a decreased risk for dementia.

14-10-2020 | Diabetes | News | Article

DKA linked to cognitive alterations in children with type 1 diabetes

Research shows moderate or severe diabetic ketoacidosis is associated with lower IQ and reduced short- and long-term memory in children with type 1 diabetes, with some impairment seen even in newly diagnosed children.

13-10-2020 | Diabetes | News | Article

Bariatric surgery cuts pancreatic cancer risk in obese individuals with diabetes

Bariatric surgery is associated with a reduced prevalence of pancreatic cancer in obese individuals with type 2 diabetes, suggest findings from a population-based study presented at UEG Week Virtual 2020.

12-10-2020 | Diabetes | News | Article

Duodenal mucosal resurfacing offers insulin-free hope for patients with type 2 diabetes

Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonists could enable some people with type 2 diabetes to discontinue insulin therapy, suggest findings from the pilot INSPIRE study.

12-10-2020 | Diabetes | News | Article

VERTIS CV secondary analyses indicate ertugliflozin protection against HF

Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

09-10-2020 | Diabetes | News | Article

Pancreatic morphology normalizes with sustained type 2 diabetes remission

Sustained remission of type 2 diabetes in DiRECT was accompanied by normalization of pancreatic morphology, say the researchers.

08-10-2020 | Diabetes | News | Article

More real-world evidence for SGLT2 inhibitor cardioprotection

Further real-world evidence demonstrates the positive cardiovascular effects of SGLT2 inhibitors in people with type 2 diabetes, in this case when compared against DPP-4 inhibitors.

07-10-2020 | Diabetes | News | Article

Real-world data support empagliflozin renoprotective effect

Real-world data suggest that the SGLT2 inhibitor empagliflozin is associated with estimated glomerular filtration rate preservation, weight loss, and a reduced risk for major adverse kidney events when compared with other antihyperglycemics among people with type 2 diabetes.

07-10-2020 | Diabetes | News | Article

Acute eGFR decline with SGLT2 inhibitors does not affect outcome

The benefits of treatment with SGLT2 inhibitors are not negated by the initial decline in estimated glomerular filtration rate commonly seen with these drugs, show post-hoc analyses of the EMPA-REG OUTCOME and CREDENCE trials.

05-10-2020 | Diabetes | News | Article

Excess mortality problem is not shrinking in young people with type 1 diabetes

Absolute mortality rates are falling among younger people with type 1 diabetes, but excess mortality relative to the general population remains high and unchanged, show Scottish national registry data presented at the virtual 56th EASD Annual Meeting.

05-10-2020 | Diabetes | News | Article

Clip-on device guides insulin injection site rotation

A device that clips onto an insulin pen can guide people with type 1 diabetes to more effectively rotate their injection site, resulting in less lipohypertrophy and glycemic variability, show the results of a proof-of-concept study.